Rhenium Skin Cancer Therapy (SCT)

Rhenium-SCT (Skin Cancer Therapy) uses the beta emitter Rhenium-188 for a non-invasive therapy in the treatment of basal cell carcinoma and squamous cell carcinoma (including Bowen’s disease).

The beta radiation emitted by rhenium-188 penetrates the tissue only 2 – 3 mm deep. It is therefore very well suited for the targeted, local treatment of superficial types of skin cancer, such as white skin cancer.

The aim of rhenium SCT is to kill precisely the tumor tissue without surgery in a painless process.The medical effect of rhenium-SCT is based on the local direct cell-destroying effect of beta radiation, which triggers both local cell death and local reactions of the body’s defense system.

More information can be found here.